Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AstraZeneca PLC (NYSE:AZN)

28.58
Delayed Data
As of Jan 13
 +0.34 / +1.20%
Today’s Change
25.55
Today|||52-Week Range
35.04
+4.61%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$72.3B

Company Description

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. It operates through the following geographical segments: UK; Continental Europe; The Americas; Asia, Africa & Australasia. It produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. It distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. The company was founded on April 6, 1999 and is headquartered in London, the United Kingdom.

Contact Information

AstraZeneca Plc
2 Kingdom Street
London Greater London W2 6BD
P:442076048000
Investor Relations:
442076048199

Employees

Shareholders

Other institutional6.53%
Mutual fund holders6.53%
Individual stakeholders--

Top Executives

Pascal SoriotChief Executive Officer & Executive Director
Pam P. ChengExecutive VP-Operations & Information Technology
Marc DunoyerChief Financial Officer & Executive Director
Sean BohenChief Medical Officer & Executive Vice President
Katarina AgeborgChief Compliance Officer